[A20-97] Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 20.05.2021

Project no.:

Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy

Result of dossier assessment:

With Child-Pugh A or no liver cirrhosis: patients with viral aetiology of HCC: indication of major added benefit. Patients with non-viral aetiology of HCC: hint of considerable added benefit. With Child-Pugh B: added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021-05-20: A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form